The use of belimumab in three cases of refractory lupus nephritis
Internal Medicine Journal · 2023
DOI: 10.1111/imj.16242 ↗Kurz gefasst
Fachartikel in der Zeitschrift Internal Medicine Journal, 2023. Verfasst von Aruni Malaweera und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Nephrology, Monash Health, Melbourne, Victoria, Australia. Hauptthemen laut MEDLINE: Lupus Nephritis, Lupus Erythematosus, Systemic. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 20 Literaturangaben.
Abstract (Originalsprache)
In recent trials for the treatment of systemic lupus erythematosus (SLE), belimumab (BLM), in addition to standard immunosuppression, has been shown to improve renal and nonrenal outcomes. We report our experience using BLM in three cases of refractory lupus nephritis (LN), where renal remission was not achieved using cyclophosphamide, mycophenolate mofetil and other immunosuppressive medications. In two of the three cases, BLM therapy led to a partial remission of LN, improvement in serological markers of SLE and disease activity, which permitted a reduction in prednisolone dosing. Treatment with efficacious therapies early in the course of LN is a desirable therapeutic strategy, to achieve early remission of proteinuria and curtail the development of irreversible chronic renal damage. Further studies are needed to provide information on the effectiveness of BLM for maintenance of remission, prevention of flares and monitoring for long‐term complications of B‐cell modulation.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Nephrology, Monash Health, Melbourne, Victoria, Australia.
- Department of Pathology, Monash Health, Melbourne, Victoria, Australia.
- Department of Rheumatology, Monash Health, Melbourne, Victoria, Australia.
- Department of Medicine, Centre for Inflammatory Diseases, Monash University, Melbourne, Victoria, Australia.
ORCID-Profile: Aruni Malaweera
Zitieren
APA
Malaweera, A., Dayan, S., Pellicano, R., Hoi, A., Kitching, A. R., & Kent, J. R. (2023). The use of belimumab in three cases of refractory lupus nephritis. Internal Medicine Journal. https://doi.org/10.1111/imj.16242
Vancouver
Malaweera A, Dayan S, Pellicano R, Hoi A, Kitching AR, Kent JR. The use of belimumab in three cases of refractory lupus nephritis. Internal Medicine Journal. 2023. doi:10.1111/imj.16242
BibTeX
@article{Malaweera2023,
author = {Malaweera, Aruni and Dayan, Sukhpal and Pellicano, Rebecca and Hoi, Alberta and Kitching, A Richard and Kent, Joanna R},
title = {The use of belimumab in three cases of refractory lupus nephritis},
journal = {Internal Medicine Journal},
year = {2023},
doi = {10.1111/imj.16242}
}
EUVIMED